Watchlist Price Alert

Autolus Therapeutics (AUTL)

NASDAQ: AUTL · Real-Time Price · USD

1.27

-0.08 (-5.93%)

At close: May 13, 2025, 3:59 PM

-5.93% (1D)

Bid	1.27
Market Cap	339.31M
Revenue (ttm)	10.12M
Net Income (ttm)	-220.66M
EPS (ttm)	-0.86
PE Ratio (ttm)	-1.48
Forward PE	-1.87
Analyst	Buy

Ask	1.4
Volume	2,876,134
Avg. Volume (20D)	1,798,726
Open	1.37
Previous Close	1.35
Day's Range	1.22 - 1.38
52-Week Range	1.10 - 5.00
Beta	1.76

About AUTL

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol AUTL

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for AUTL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Autolus Therapeutics has released their quartely earnings on May 8, 2025:

Revenue of $8.98M exceeds estimates by $7.39M, with -10.99% YoY decline.

EPS of -0.26 misses estimates by 0.00, with -8.33% YoY decline.

Why Price Moved

6 days ago

+9.76%

Autolus Therapeutics shares are trading higher fol... Unlock content with Pro Subscription

1 month ago

-9.03%

Autolus Therapeutics shares are trading lower after Truist Securities cut its price target on the stock from $11 to $10.

News

3 days ago · seekingalpha.com

Autolus Therapeutics plc (AUTL) Q1 2025 Earnings Call Transcript

Autolus Therapeutics plc (NASDAQ:AUTL ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Amanda Cray – Executive Director-Investor Relations Christian Itin – Chief Executiv...

1 month ago · seekingalpha.com

Autolus Therapeutics plc (AUTL) Q4 2024 Earnings Conference Call Transcript

Autolus Therapeutics plc (NASDAQ:AUTL ) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ET Company Participants Amanda Cray - IR Christian Itin - CEO Rob Dolski - CFO Conference Call Participa...

2 months ago · seekingalpha.com

Autolus Therapeutics: Beaten Down, Cash Rich, Poised To Launch A CAR-T Cell Therapy

Autolus Therapeutics' main focus is on obe-cel, a CAR T-cell therapy for B-cell ALL, with a strong likelihood of approval. AUTL has $657.1 million in cash, providing a cash runway of approximately 3 y...